Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Epithelial C5aR1 Signaling Enhances Uropathogenic Escherichia coli Adhesion to Human Renal Tubular Epithelial Cells.

Song Y, Wu KY, Wu W, Duan ZY, Gao YF, Zhang LD, Chong T, Garstka MA, Zhou W, Li K.

Front Immunol. 2018 May 1;9:949. doi: 10.3389/fimmu.2018.00949. eCollection 2018.

2.

A flexible MHC class I multimer loading system for large-scale detection of antigen-specific T cells.

Luimstra JJ, Garstka MA, Roex MCJ, Redeker A, Janssen GMC, van Veelen PA, Arens R, Falkenburg JHF, Neefjes J, Ovaa H.

J Exp Med. 2018 May 7;215(5):1493-1504. doi: 10.1084/jem.20180156. Epub 2018 Apr 17.

3.

Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis.

Bai F, Zheng W, Dong Y, Wang J, Garstka MA, Li R, An J, Ma H.

Oncotarget. 2017 Nov 1;9(1):1266-1278. doi: 10.18632/oncotarget.22260. eCollection 2018 Jan 2.

4.

Corrigendum to "The Controversial C5a Receptor C5aR2: Its Role in Health and Disease".

Zhang T, Garstka MA, Li K.

J Immunol Res. 2017;2017:6073961. doi: 10.1155/2017/6073961. Epub 2017 Nov 1.

5.

The Controversial C5a Receptor C5aR2: Its Role in Health and Disease.

Zhang T, Garstka MA, Li K.

J Immunol Res. 2017;2017:8193932. doi: 10.1155/2017/8193932. Epub 2017 Jun 15. Review. Erratum in: J Immunol Res. 2017;2017:6073961.

6.

An ER-Associated Pathway Defines Endosomal Architecture for Controlled Cargo Transport.

Jongsma ML, Berlin I, Wijdeven RH, Janssen L, Janssen GM, Garstka MA, Janssen H, Mensink M, van Veelen PA, Spaapen RM, Neefjes J.

Cell. 2016 Jun 30;166(1):152-66. doi: 10.1016/j.cell.2016.05.078.

7.

The first step of peptide selection in antigen presentation by MHC class I molecules.

Garstka MA, Fish A, Celie PH, Joosten RP, Janssen GM, Berlin I, Hoppes R, Stadnik M, Janssen L, Ovaa H, van Veelen PA, Perrakis A, Neefjes J.

Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1505-10. doi: 10.1073/pnas.1416543112. Epub 2015 Jan 20.

8.

How to target MHC class II into the MIIC compartment.

Garstka MA, Neefjes J.

Mol Immunol. 2013 Sep;55(2):162-5. doi: 10.1016/j.molimm.2012.10.022. Epub 2012 Nov 27. Review.

PMID:
23200228
9.

Tapasin dependence of major histocompatibility complex class I molecules correlates with their conformational flexibility.

Garstka MA, Fritzsche S, Lenart I, Hein Z, Jankevicius G, Boyle LH, Elliott T, Trowsdale J, Antoniou AN, Zacharias M, Springer S.

FASEB J. 2011 Nov;25(11):3989-98. doi: 10.1096/fj.11-190249. Epub 2011 Aug 11.

PMID:
21836024
10.

EBV protein BNLF2a exploits host tail-anchored protein integration machinery to inhibit TAP.

Horst D, Favaloro V, Vilardi F, van Leeuwen HC, Garstka MA, Hislop AD, Rabu C, Kremmer E, Rickinson AB, High S, Dobberstein B, Ressing ME, Wiertz EJ.

J Immunol. 2011 Mar 15;186(6):3594-605. doi: 10.4049/jimmunol.1002656. Epub 2011 Feb 4.

11.

Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation.

Horst D, van Leeuwen D, Croft NP, Garstka MA, Hislop AD, Kremmer E, Rickinson AB, Wiertz EJ, Ressing ME.

J Immunol. 2009 Feb 15;182(4):2313-24. doi: 10.4049/jimmunol.0803218.

Supplemental Content

Loading ...
Support Center